Objective: This study aimed to confirm the potential of growth-related gene product β (GROβ) as a biomarker for colorectal cancer. We compared serum GROβ levels in patients with colorectal cancer, healthy individuals and individuals with non-tumor diseases.
Methods: We measured serum GROβ levels with enzyme-linked immunosorbent assay in patients with colorectal cancer (123 preoperative samples and 66 postoperative samples), 88 healthy controls and 125 individuals with other diseases. Serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were measured in all samples with an immunoluminometric assay. Statistical analyses were performed to determine associations between serum GROβ levels and clinical parameters for colorectal cancer. A receiver operating characteristic (ROC) curve was analyzed for GROβ, CEA and CA19-9.
Results: The serum GROβ levels were much higher in patients with colorectal cancer (median: 96.15 pg/ml) than those in healthy controls (median: 43.28 pg/ml, P < 0.01) and other disease controls (median: 57.30 pg/ml, P < 0.01). Serum GROβ levels in colorectal cancer were correlated positively with tumor-node-metastasis staging (P < 0.01) and the depth of infiltration (P < 0.05), but not with the histological grade, tumor embolus, lymph node metastasis, gross pathologic tumor type, or patient gender. The sensitivity and specificity of the assay for serum GROβ were 56.1% (69/123) and 95.31% (203/213), respectively. The area under the ROC curve constructed with GROβ (0.834) was larger than that constructed with CEA (0.739) or CA19-9 (0.676) for discriminating colorectal cancer from matched controls.
Conclusion: These preliminary results suggested that the serum GROβ level could be a useful biomarker for colorectal cancer diagnoses.
Keywords: CA19-9; CEA; GROβ; biomarker; colorectal cancer.